Cocrystal Pharma appoints Carol Brosgart to board of directors
COCP•Cocrystal Pharma appointed Carol Brosgart to its board, effective August 12, 2026. Brosgart spent more than a decade at Gilead Sciences, helping develop Viread and Hepsera.
1. Board appointment
Cocrystal Pharma appointed Carol Brosgart to its board of directors, effective August 12, 2026. Brosgart spent more than a decade at Gilead Sciences, helping develop the antiviral therapies Viread and Hepsera.
